Carles Escriu
@carlesescriu.bsky.social
Thoracic Medical Oncologist and Honorary Clinical Lecturer. Liverpool, England, UK.
Reposted by Carles Escriu
The job of a doctor is not, necessarily, to be kind or popular or fluffy or liked.
It is to do and to say the right thing for your patients.
However difficult it may be to do so.
However tough you may find it.
Many institutions pretend otherwise, including the GMC.
Here's why they're wrong 🧵
It is to do and to say the right thing for your patients.
However difficult it may be to do so.
However tough you may find it.
Many institutions pretend otherwise, including the GMC.
Here's why they're wrong 🧵
May 18, 2025 at 4:15 PM
The job of a doctor is not, necessarily, to be kind or popular or fluffy or liked.
It is to do and to say the right thing for your patients.
However difficult it may be to do so.
However tough you may find it.
Many institutions pretend otherwise, including the GMC.
Here's why they're wrong 🧵
It is to do and to say the right thing for your patients.
However difficult it may be to do so.
However tough you may find it.
Many institutions pretend otherwise, including the GMC.
Here's why they're wrong 🧵
“How Does Paris Stay Paris? By Pouring Billions Into Public Housing.”
“1/4 of residents in the French capital live in government-owned housing, part of an aggressive plan to keep lower-income Parisians— & their businesses— in the city.”
Paris innovation isn’t just about people-places & bike-lanes.
“1/4 of residents in the French capital live in government-owned housing, part of an aggressive plan to keep lower-income Parisians— & their businesses— in the city.”
Paris innovation isn’t just about people-places & bike-lanes.
How Does Paris Stay Paris? By Pouring Billions Into Public Housing (Published 2024)
One quarter of residents in the French capital live in government-owned housing, part of an aggressive plan to keep lower-income Parisians — and their businesses — in the city.
www.nytimes.com
April 28, 2025 at 5:43 AM
Easy access to diagnostic investigations in primary care is likely to diagnose cancer earlier and prolong patient's lives.
Optimal management of comorbidities is also likely to facilitate access to radical cancer therapies.
NHS cancer funding needs to take the entire picture into account.
Optimal management of comorbidities is also likely to facilitate access to radical cancer therapies.
NHS cancer funding needs to take the entire picture into account.
#Lungcancer is rising in young, non-smoking women. 📈
Too many face misdiagnosis & delays because it’s not expected in people their age.
Clair, Hayley, Harriet, Kizz, Becky, Stacy, Jade, & Emma were all diagnosed with stage 4 ALK+ lung cancer in their 20s, 30s, or early 40s.
#LCSM
Too many face misdiagnosis & delays because it’s not expected in people their age.
Clair, Hayley, Harriet, Kizz, Becky, Stacy, Jade, & Emma were all diagnosed with stage 4 ALK+ lung cancer in their 20s, 30s, or early 40s.
#LCSM
March 8, 2025 at 8:54 AM
Easy access to diagnostic investigations in primary care is likely to diagnose cancer earlier and prolong patient's lives.
Optimal management of comorbidities is also likely to facilitate access to radical cancer therapies.
NHS cancer funding needs to take the entire picture into account.
Optimal management of comorbidities is also likely to facilitate access to radical cancer therapies.
NHS cancer funding needs to take the entire picture into account.
Reposted by Carles Escriu
Graham Warren on smoking cessation in lung cancer pts.
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
March 5, 2025 at 9:23 AM
Graham Warren on smoking cessation in lung cancer pts.
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
Extraordinary data:
🔺 $3.4bn cost of failed treatment if don’t quit
🔺 ⬇️ 45% mortality if quit
🔺Less frequent reminders more effective than more
🔺 Incredible ⬆️ survival if quit <6m after diagnosis: approx 4yr mOS benefit
Sensational talk 🤯
SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.
Translational studies to aid patient selection will now be more needed than ever.
Translational studies to aid patient selection will now be more needed than ever.
March 5, 2025 at 12:56 PM
SCLC was indeed the star at #BTOG25. Looking forward to the benefit (and challenges) of novel therapeutic strategies.
Translational studies to aid patient selection will now be more needed than ever.
Translational studies to aid patient selection will now be more needed than ever.
Reposted by Carles Escriu
New 5-year data from the CROWN trial in Asian ALK+ #lungcancer: Lorlatinib continues to show longer progression-free survival than crizotinib, with 63% progression-free at 5 years vs. 7% with crizotinib. Strong intracranial response rates too. www.jto.org/article/S155... #LCSM
First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study
Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed
significantly longer progression-free survival (PFS) than crizotinib in the phase
3 CROWN trial (NCT03052608) in patie...
www.jto.org
March 2, 2025 at 10:32 AM
New 5-year data from the CROWN trial in Asian ALK+ #lungcancer: Lorlatinib continues to show longer progression-free survival than crizotinib, with 63% progression-free at 5 years vs. 7% with crizotinib. Strong intracranial response rates too. www.jto.org/article/S155... #LCSM
Reposted by Carles Escriu
The 2nd part of the Therapeutics Symposium at #BTOG25 Annual Conference is chaired by
@carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering “Refining Patient Selection”.
btog.org/23rd-btog-an...
@carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering “Refining Patient Selection”.
btog.org/23rd-btog-an...
February 18, 2025 at 3:51 PM
The 2nd part of the Therapeutics Symposium at #BTOG25 Annual Conference is chaired by
@carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering “Refining Patient Selection”.
btog.org/23rd-btog-an...
@carlesescriu.bsky.social and @tnewsomdavis.bsky.social, covering “Refining Patient Selection”.
btog.org/23rd-btog-an...